Consensus guidelines for patient management can increase disease awareness and education, and facilitate evidence-based clinical decision-making. Nevertheless, new gout recommendations leave a 'déjà vu' impression. Novel evidence from clinical trials is needed to robustly advance patient care and build the next generation of guidelines.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sivera, F. et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203325.
Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. (Hoboken). 64, 1447–1461 (2012).
Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken). 64, 1431–1446 (2012).
Zhang, W. et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 265, 1301–1311 (2006).
Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312–1324 (2006).
Terkeltaub, R. A., Furst, D. E., Bennett, K., Kook, K. A., Crockett, R. S. & Davis, M. W. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 62, 1060–1068 (2012).
Perez-Ruiz, F., Calabozo, M., Pijoan, J. I., Herrero-Beites, A. M., Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 47, 356–360 (2002).
Neogi, T. et al. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum. 64, 327–338 (2012).
Rees, F., Jenkins, W. & Doherty, M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann. Rheum. Dis. 72, 826–830 (2013).
Mikuls, T. R. Quality of care in gout: from measurement to improvement. Clin. Exp. Rheumatol. 25, (Suppl. 47) 114–119 (2007).
Acknowledgements
The author's work is supported financially by the Veterans Affairs (VA) Research Service of the USA.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
R. Terkeltaub declares that he has acted as a consultant for Abbvie, ARDEA, BioCryst, Mallinkrodt, Novartis, Pfizer, Regeneron, Savient, Sobi, Takeda and UCB.
Rights and permissions
About this article
Cite this article
Terkeltaub, R. Multinational gout guidelines: how do we move beyond 'déjà vu'?. Nat Rev Rheumatol 9, 567–569 (2013). https://doi.org/10.1038/nrrheum.2013.142
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2013.142
